Sonazoid辅助高强度聚焦超声消融治疗晚期肝脏恶性病变的安全性:一项单臂临床研究
本研究为单臂临床研究,纳入17例晚期原发性肝癌或肝转移并拟在HIFU治疗中接受Sonazoid辅助的患者,评估Sonazoid辅助HIFU的安全性。治疗后1周内行血清学检查、1个月内监测副作用,1个月后行增强MRI评估疗效并随访1年。结果显示Sonazoid辅助HIFU未发现严重副作用,但疗效需进一步对照临床研究探索。
要点
- Sonazoid辅助HIFU治疗晚期肝脏恶性病变未发现严重副作用。
- 治疗后71.6%(12/17)患者ALT轻度升高,治疗前后均值分别为22(14,35)U/L和36(25,41)U/L(Z=1.947,p=0.051)。
- 76.5%患者出现皮肤及皮下软组织轻度或明显水肿,但无严重副作用。
核心结论
- Sonazoid用于提高HIFU消融晚期肝脏恶性病变的效率是安全可行的,但其疗效需在更多对照临床研究中探索。
研究设计与样本
- 单臂临床研究,纳入17例诊断为晚期原发性肝癌或肝转移并拟在HIFU治疗中接受Sonazoid辅助的患者(12男5女,平均年龄58岁,范围46-73岁),包括11例肝细胞癌、2例肝转移和4例胆管癌;治疗后1周内行血清学检查,1个月内监测副作用,治疗后1个月行增强MRI评估疗效,1年后行短期随访。
局限性
- Sonazoid辅助HIFU的治疗疗效需在更多对照临床研究中探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the study described here was to evaluate the safety of Sonazoid-assisted high-intensity focused ultrasound (HIFU) in the treatment of advanced malignant liver lesions.
METHODS: A single-arm study was designed to enroll participants who were diagnosed with advanced primary liver cancer or liver metastases and proposed to receive Sonazoid assistance during HIFU treatment. Serological examination was conducted within 1 wk, and side effects in each patient were monitored for 1 mo. To evaluate therapeutic efficacy, the contrast-enhanced magnetic resonance imaging was performed 1 mo after treatment, and short-term follow-up was conducted a year later.
RESULTS: A total of 17 participants (12 male, 5 female) with an average age of 58 y (range: 46-73 y) were enrolled, including 11 patients with hepatocellular carcinoma, 2 patients with hepatic metastasis and 4 patients with cholangiocarcinoma. The total volume of tumor mass was 111.82 (11.01-272.30) cm3. The average total ablation time for a patient was 2021 ± 1030 s, and the energy efficiency factor was 5979.7 (3108.0, 45634.5) J/cm3. Immediately after HIFU treatment, 1 patient (5.9%) achieved complete response (CR), 4 patients (23.5%) had a moderate response, 8 patients (47.1%) had partial reperfusion and 4 patients (23.5%) had stable disease (SD). The average ablation rate for all the tumors was 51.5 ± 26.7%. The level of glutamic-pyruvic transaminase (ALT) was mildly increased in 71.6% (12/17) of patients after HIFU therapy. Mean ALT values before and after treatment were 22 (14, 35) U/L and 36 (25, 41) U/L, respectively (Z = 1.947, p = 0.051). Mild or obvious edema in skin and subcutaneous soft tissues were observed in 76.5% of patients, but no serious side effects were found. Twelve months after treatment, the follow-up results revealed that 1 patient (5.8%) achieved a CR, 8 patients (47.1%) had SD and 8 patients (47.1%) had progressive disease. The estimated median time to progression was 11 mo after treatment, with a 95% confidence interval of 6, 11 for all involved patients.
CONCLUSION: Use of Sonazoid is safe and feasible for improving HIFU ablation efficiency during the treatment of advanced malignant liver lesions. The therapeutic efficacy of Sonazoid-assisted HIFU needs to be explored in additional controlled clinical investigations.
引用
- Zhou H, Li F, Luo L, et al. Safety of Sonazoid in Assisting High-Intensity Focused Ultrasound Ablation Therapy for Advanced Liver Malignant Lesions: A Single-Arm Clinical Study. Ultrasound Med Biol. 2023. PMID: 37865612. doi:10.1016/j.ultrasmedbio.2023.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。